Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation.
about
Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosisThe rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaksIon Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosisA Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, RussiaVitamins A & D inhibit the growth of mycobacteria in radiometric cultureDiagnostic Molecular Mycobacteriology in Regions With Low Tuberculosis Endemicity: Combining Real-time PCR Assays for Detection of Multiple Mycobacterial Pathogens With Line Probe Assays for Identification of Resistance MutationsFIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug ResistanceUtility of Second-Generation Line Probe Assay (Hain MTBDRplus) Directly on 2-Month Sputum Specimens for Monitoring Tuberculosis Treatment Response.Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosisThe structural modeling of the interaction between levofloxacin and the Mycobacterium tuberculosis gyrase catalytic site sheds light on the mechanisms of fluoroquinolones resistant tuberculosis in Colombian clinical isolates.Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13.The pyrazinamide susceptibility breakpoint above which combination therapy fails.Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates.Molecular basis for the selectivity of antituberculosis compounds capreomycin and viomycin.Comparison of the mycobacterium growth indicator tube method and the method of proportion for drug susceptibility testing of mycobacterium tuberculosisImpact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assayDefining multidrug-resistant tuberculosis: correlating GenoType MTBDRplus assay results with minimum inhibitory concentrations.Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide.Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosisEffects of Halide Ions on the Carbamidocyclophane Biosynthesis in Nostoc sp. CAVN2.Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis.The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs.Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis.Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.Diagnostic implications of inconsistent results obtained with the Xpert MTB/Rif assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance.Evaluation of the AID TB resistance line probe assay for rapid detection of genetic alterations associated with drug resistance in Mycobacterium tuberculosis strains.Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug effluxEvaluation of the Cepheid Xpert MTB/RIF assay.Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591.Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.The Resistant-Population Cutoff (RCOFF): a New Concept for Improved Characterization of Antimicrobial Susceptibility Patterns of Non-Wild-Type Bacterial Populations.Integrating the Xpert MTB/RIF assay into a diagnostic workflow for rapid detection of Mycobacterium tuberculosis in a low-prevalence area.Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first- and second-line agents.Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence.Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.Nonmutational compensation of the fitness cost of antibiotic resistance in mycobacteria by overexpression of tlyA rRNA methylase.embB306 mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosis.
P2860
Q28482174-9094B79A-E00F-4556-AE3F-8E8CF4FF182AQ28488204-8C36878B-CCC4-4195-8D6B-438E9C570982Q28550401-6B02706D-D812-4D91-9825-5A7D28B67454Q28554618-295090BE-AF33-4CDE-B006-211884DAE869Q28740534-89B23CE0-C666-4CCD-8370-A036ACFBE1DAQ28831411-AFBE08B5-A7A6-45EC-B30B-91D0A5CB76F2Q33458900-2CE1CCA0-23BC-420F-B45A-4E79FD41583FQ33603890-4DCF9E74-29C0-4B92-8FF1-8148CB8B9692Q33607162-16E40351-B702-4FF1-BE2D-E73CDADD4EEDQ33616718-39798946-1136-48E4-8426-A5274879D2CAQ33902627-93F198B3-15D1-40AD-AA92-F5F77F60C342Q34034401-F2E79CAF-C28F-4072-BF2E-03FA12CCD2D4Q34046259-0DD96F0F-1680-444B-B791-6974D84793D8Q34631045-21B2FD91-BFC6-401F-9E3D-DF685658E5A7Q34666985-A1D13455-0656-457E-8BA3-726B83B05EEBQ34922554-BAA4719A-CDD0-4FD8-BDBF-E98470B0FADCQ35181330-9149750D-CA6D-41F2-94D7-5E7DFF13C95FQ35554602-0F8034C0-8C14-472D-99DF-757B8A15E549Q35689060-1E58A90A-CB19-4335-A8C3-5BD857EA5B3BQ35689424-20717B7F-BF34-4EB0-9925-4ABEB9B72440Q35902819-C38E9A7F-501C-481F-87F8-B85CD04633A5Q36018737-FF569EED-2C3F-43EB-AD20-A3B0CD64B022Q36230709-ABDDDE51-4B0A-4C13-B313-4B80017668B4Q36773017-76170AEC-EC85-4CE8-B4E9-8755E759A536Q37124036-B3114C13-62B5-4944-A4A0-A60A95DCB353Q37125148-F1B32C8F-AB4C-4879-BCF0-6F7B8B78FCB7Q37643455-33FD1EEC-C167-4EBD-B5BD-A24E85943691Q37679508-B7CDBDB6-425A-4C4F-BB48-E2092B4CBD2DQ38265418-1F8BBAC6-6E13-44A4-8F1D-C050A39B0181Q38929849-BA9FFE6E-5A39-4C18-9F6C-66FD6E87CF3BQ39080590-73EE4507-3BB7-4CF3-BCEE-6A405BB77360Q40282057-41DDFD2A-AD95-4CF8-9679-AD1ABF8C5C0FQ40672387-E9F265CF-1E30-4625-83A0-7CA7CAB5E68EQ41428768-3E6C87E1-BAB4-4B87-89D9-62A3A6A326AFQ41579477-64902E1B-1843-4B03-ACA2-228A90A38191Q41932850-E7119242-3551-420C-9727-F0E711162D72Q42430318-1CF82876-1B05-4F7B-9416-0940E2B6F62EQ46168942-D633A2C6-F6D5-477A-B0E2-BD573F38A458Q46349510-8D29F060-0A08-4525-ABDA-F66A05E44E45Q46639370-1FE0CB62-4E4E-41DF-8F7E-058D32CF0378
P2860
Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Quantitative drug susceptibili ...... and EpiCenter instrumentation.
@en
Quantitative drug susceptibili ...... and EpiCenter instrumentation.
@nl
type
label
Quantitative drug susceptibili ...... and EpiCenter instrumentation.
@en
Quantitative drug susceptibili ...... and EpiCenter instrumentation.
@nl
prefLabel
Quantitative drug susceptibili ...... and EpiCenter instrumentation.
@en
Quantitative drug susceptibili ...... and EpiCenter instrumentation.
@nl
P2093
P2860
P356
P1476
Quantitative drug susceptibili ...... and EpiCenter instrumentation.
@en
P2093
Burkhard Springer
Claudia Ritter
Katja Lucke
Romana Calligaris-Maibach
P2860
P304
P356
10.1128/JCM.02501-08
P407
P577
2009-04-01T00:00:00Z